Robotic versus open radical cystectomy for bladder cancer in adults (Review)


www.cochranelibrary.com
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Header</td>
<td>1</td>
</tr>
<tr>
<td>Abstract</td>
<td>1</td>
</tr>
<tr>
<td>Plain Language Summary</td>
<td>2</td>
</tr>
<tr>
<td>Summary of Findings for the Main Comparison</td>
<td>4</td>
</tr>
<tr>
<td>Background</td>
<td>6</td>
</tr>
<tr>
<td>Objectives</td>
<td>6</td>
</tr>
<tr>
<td>Methods</td>
<td>6</td>
</tr>
<tr>
<td>Results</td>
<td>9</td>
</tr>
<tr>
<td>Figure 1</td>
<td>10</td>
</tr>
<tr>
<td>Figure 2</td>
<td>13</td>
</tr>
<tr>
<td>Figure 3</td>
<td>15</td>
</tr>
<tr>
<td>Figure 4</td>
<td>16</td>
</tr>
<tr>
<td>Discussion</td>
<td>17</td>
</tr>
<tr>
<td>Authors' Conclusions</td>
<td>18</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>19</td>
</tr>
<tr>
<td>References</td>
<td>19</td>
</tr>
<tr>
<td>Characteristics of Studies</td>
<td>23</td>
</tr>
<tr>
<td>Data and Analyses</td>
<td>43</td>
</tr>
<tr>
<td>Analysis 1.1. Comparison 1 Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 1 Recurrence-free survival</td>
<td>43</td>
</tr>
<tr>
<td>Analysis 1.2. Comparison 1 Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 2 Major postoperative complication rates (Clavien 3 to 5)</td>
<td>44</td>
</tr>
<tr>
<td>Analysis 1.3. Comparison 1 Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 3 Minor postoperative complication rates (Clavien 1 and 2)</td>
<td>45</td>
</tr>
<tr>
<td>Analysis 1.4. Comparison 1 Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 4 Transfusion rate</td>
<td>46</td>
</tr>
<tr>
<td>Analysis 1.5. Comparison 1 Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 5 Hospital stay</td>
<td>47</td>
</tr>
<tr>
<td>Analysis 1.6. Comparison 1 Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 6 Quality of life</td>
<td>48</td>
</tr>
<tr>
<td>Analysis 1.7. Comparison 1 Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 7 Positive margin</td>
<td>49</td>
</tr>
<tr>
<td>Appendices</td>
<td>49</td>
</tr>
<tr>
<td>Contributions of Authors</td>
<td>50</td>
</tr>
<tr>
<td>Declarations of Interest</td>
<td>51</td>
</tr>
<tr>
<td>Sources of Support</td>
<td>51</td>
</tr>
<tr>
<td>Differences between Protocol and Review</td>
<td>52</td>
</tr>
<tr>
<td>Notes</td>
<td>52</td>
</tr>
</tbody>
</table>
Robotic versus open radical cystectomy for bladder cancer in adults

Bhavan Prasad Rai1, Jasper Bondad2, Nikhil Vasdev3, Jim Adshead3, Tim Lane3, Kamran Ahmed4, Mohammed S Khan4, Prokar Dasgupta4, Khurshid Guru5, Piotr L Chlosta6, Omar M Aboumarzouk7

1Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK. 2Department of Urology, Southend Hospital, Westcliff-on-Sea, UK. 3Department of Urology, Lister Hospital, Stevenage, UK. 4MRC Centre for Transplantation, Division of Transplantation Immunology and Mucosal Biology, School of Medicine, King’s College London, London, UK. 5Department of Urology, Roswell Park Cancer Institute, Buffalo, New York, USA. 6Department of Urology, Jagiellonian University, Collegium Medicum, Krakow, Poland. 7Department of Urology, NHS Greater Glasgow and Clyde, Glasgow, UK

Contact address: Omar M Aboumarzouk, Department of Urology, NHS Greater Glasgow and Clyde, Queen Elizabeth University Hospital, Glasgow, Scotland, UK. aboumarzouk@gmail.com, drbigo31262@gmail.com.

Editorial group: Cochrane Urology Group.


Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

It has been suggested that in comparison with open radical cystectomy, robotic-assisted radical cystectomy results in less blood loss, shorter convalescence, and fewer complications with equivalent short-term oncological and functional outcomes; however, uncertainty remains as to the magnitude of these benefits.

Objectives

To assess the effects of robotic-assisted radical cystectomy versus open radical cystectomy in adults with bladder cancer.

Search methods

Review authors conducted a comprehensive search with no restrictions on language of publication or publication status for studies comparing open radical cystectomy and robotic-assisted radical cystectomy. The date of the last search was 1 July 2018 for the Cochrane Central Register of Controlled Trials, MEDLINE (1999 to July 2018), PubMed Embase (1999 to July 2018), Web of Science (1999 to July 2018), Cancer Research UK (www.cancerresearchuk.org/), and the Institute of Cancer Research (www.icr.ac.uk/). We searched the following trials registers: ClinicalTrials.gov (clinicaltrials.gov/), BioMed Central International Standard Randomized Controlled Trials Number (ISRCTN) Registry (www.isrctn.com), and the World Health Organization International Clinical Trials Registry Platform.

Selection criteria

We searched for randomised controlled trials that compared robotic-assisted radical cystectomy (RARC) with open radical cystectomy (ORC).
Data collection and analysis
This study was based on a published protocol. Primary outcomes of the review were recurrence-free survival and major postoperative complications (class III to V). Secondary outcomes were minor postoperative complications (class I and II), transfusion requirement, length of hospital stay (days), quality of life, and positive margins (%). Three review authors independently assessed relevant titles and abstracts of records identified by the literature search to determine which studies should be assessed further. Two review authors assessed risk of bias using the Cochrane risk of bias tool and rated the quality of evidence according to GRADE. We used Review Manager 5 to analyse the data.

Main results
We included in the review five randomised controlled trials comprising a total of 541 participants. Total numbers of participants included in the ORC and RARC cohorts were 270 and 271, respectively.

Primary outcomes
**Time-to-recurrence**: Robotic cystectomy and open cystectomy may result in a similar time to recurrence (hazard ratio (HR) 1.05, 95% confidence interval (CI) 0.77 to 1.43); 2 trials; low-certainty evidence). In absolute terms at 5 years of follow-up, this corresponds to 16 more recurrences per 1000 participants (95% CI 79 fewer to 123 more) with 431 recurrences per 1000 participants for ORC. We downgraded the certainty of evidence for study limitations and imprecision.

**Major complications (Clavien grades 3 to 5)**: Robotic cystectomy and open cystectomy may result in similar rates of major complications (risk ratio (RR) 1.06, 95% CI 0.76 to 1.48); 5 trials; low-certainty evidence). This corresponds to 11 more major complications per 1000 participants (95% CI 44 fewer to 89 more). We downgraded the certainty of evidence for study limitations and imprecision.

Secondary outcomes
**Minor complications (Clavien grades 1 and 2)**: We are very uncertain whether robotic cystectomy may reduce minor complications (very low-certainty evidence). We downgraded the certainty of evidence for study limitations and for very serious imprecision.

**Transfusion rate**: Robotic cystectomy probably results in substantially fewer transfusions than open cystectomy (RR 0.58, 95% CI 0.43 to 0.80; 2 trials; moderate-certainty evidence). This corresponds to 193 fewer transfusions per 1000 participants (95% CI 262 fewer to 92 fewer) based on 460 transfusion per 1000 participants for ORC. We downgraded the certainty of evidence for study limitations.

**Hospital stay**: Robotic cystectomy may result in a slightly shorter hospital stay than open cystectomy (mean difference (MD) -0.67, 95% CI -1.22 to -0.12); 5 trials; low-certainty evidence). We downgraded the certainty of evidence for study limitations and imprecision.

**Quality of life**: Robotic cystectomy and open cystectomy may result in a similar quality of life (standard mean difference (SMD) 0.08, 95% CI 0.32 lower to 0.16 higher; 3 trials; low-certainty evidence). We downgraded the certainty of evidence for study limitations and imprecision.

**Positive margin rates**: Robotic cystectomy and open cystectomy may result in similar positive margin rates (RR 1.16, 95% CI 0.56 to 2.40; 5 trials; low-certainty evidence). This corresponds to 8 more (95% CI 21 fewer to 67 more) positive margins per 1000 participants based on 48 positive margins per 1000 participants for ORC. We downgraded the certainty of evidence for study limitations and imprecision.

Authors’ conclusions
Robotic cystectomy and open cystectomy may have similar outcomes with regard to time to recurrence, rates of major complications, quality of life, and positive margin rates (all low-certainty evidence). We are very uncertain whether the robotic approach reduces rates of minor complications (very low-certainty evidence), although it probably reduces the risk of blood transfusions substantially (moderate-certainty evidence) and may reduce hospital stay slightly (low-certainty evidence). We were unable to conduct any of the preplanned subgroup analyses to assess the impact of patient age, pathological stage, body habitus, or surgeon expertise on outcomes. This review did not address issues of cost-effectiveness.

**PLAIN LANGUAGE SUMMARY**
Robotic versus open radical cystectomy for bladder cancer in adults

Review question

Robotic versus open radical cystectomy for bladder cancer in adults (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
For patients with bladder cancer that involves the deep muscle wall, does use of a robotic device lead to better or worse outcomes than open surgery?

**Background**

Patients with bladder cancer that involves the deep muscle wall are best treated by an operation that removes the entire bladder and creates an artificial bladder or channel from the bowel to allow urine to drain to the outside world. This has been done traditionally through open surgery using one large incision. Recently, this operation has been performed with robotic assistance using several small incisions. It is uncertain which approach is better.

**Study characteristics**

We performed a comprehensive literature search until 1 July 2018. We found five trials comparing robotic assisted versus open surgery. The total number of participants in these trials was 541. Four studies were conducted in the USA and one in the UK.

**Key results**

There may be little to no difference in the time to recurrence, the rate of major complications or minor complications, quality of life, and rates of positive margins (signalling that cancer may have been left behind). Robotic surgery probably results in fewer blood transfusions and may lead to a slightly shorter hospital stay when compared with open surgery.

**Certainty of evidence**

Reviewers rated the certainty of evidence as low for most outcomes, except for minor complications (very low) and transfusions (moderate). This means that the true results for these outcomes could be quite different.
## Summary of Findings for the Main Comparison

Robotic-assisted laparoscopic vs open radical cystectomy for bladder cancer in adults

**Patient or population:** bladder cancer in adults  
**Setting:** tertiary care centres in the United States and the United Kingdom  
**Intervention:** robotic-assisted laparoscopic cystectomy  
**Comparison:** open radical cystectomy

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>No. of participants (studies) Follow-up</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Relative effect (95% CI)</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Risk with open radical cystectomy</th>
<th>Risk difference with robotic-assisted laparoscopic cystectomy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time to recurrence (here: recurrence rate at 5 years)(^1) assessed with clinical examination and imaging</td>
<td>277 (2 RCTs)</td>
<td>⊕⊕⊕⊕ LOW(^a, b)</td>
<td>HR 1.05 (0.77 to 1.43)</td>
<td>Study population</td>
<td>431 per 1000</td>
<td>16 more per 1000 (79 fewer to 123 more)</td>
</tr>
<tr>
<td>Major postoperative complications assessed with Clavien-Dindo system (rated grade 3 to 5)</td>
<td>541 (5 RCTs)</td>
<td>⊕⊕⊕⊕ LOW(^b,c)</td>
<td>RR 1.06 (0.76 to 1.48)</td>
<td>Study population</td>
<td>185 per 1000</td>
<td>11 more per 1000 (44 fewer to 89 more)</td>
</tr>
<tr>
<td>Minor postoperative complications assessed with Clavien-Dindo system (rated grade 1 or 2)</td>
<td>423 (4 RCTs)</td>
<td>⊕⊕⊕⊕ VERY LOW(^c,d)</td>
<td>RR 0.82 (0.58 to 1.17)</td>
<td>Study population</td>
<td>443 per 1000</td>
<td>80 fewer per 1000 (186 fewer to 75 more)</td>
</tr>
<tr>
<td>Transfusion rate assessed with transfused units of packed red blood cells</td>
<td>326 (2 RCTs)</td>
<td>⊕⊕⊕⊕ MODERATE(^c)</td>
<td>RR 0.58 (0.43 to 0.80)</td>
<td>Study population</td>
<td>460 per 1000</td>
<td>193 fewer per 1000 (262 fewer to 92 fewer)</td>
</tr>
</tbody>
</table>

\(^1\) Time to recurrence was assessed with clinical examination and imaging.
<table>
<thead>
<tr>
<th>Outcome Description</th>
<th>Study Count</th>
<th>GRADE Evidence Grade</th>
<th>Quality of Life (higher scores indicate better quality of life)</th>
<th>Hospital Stay in Days</th>
<th>Study Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital stay assessed in days</td>
<td>541 (5 RCTs)</td>
<td>LOW&lt;sup&gt;b,c&lt;/sup&gt;</td>
<td>-</td>
<td>Mean hospital stay ranged from 5.1 to 11.9 days MD 0.67 days lower (1.22 lower to 0.12 lower)</td>
<td></td>
</tr>
<tr>
<td>Quality of life (higher scores indicate better quality of life) assessed with SMD calculated from various validated quality of life instruments Scale from 0 to 1</td>
<td>270 (3 RCTs)</td>
<td>LOW&lt;sup&gt;c,e&lt;/sup&gt;</td>
<td>-</td>
<td>Mean quality of life (higher scores indicate better quality of life) was 0 SD SMD 0.08 SD lower (0.32 lower to 0.16 higher)</td>
<td></td>
</tr>
<tr>
<td>Positive margins assessed through pathological evaluation of cystectomy specimen</td>
<td>541 (5 RCTs)</td>
<td>LOW&lt;sup&gt;b,c&lt;/sup&gt;</td>
<td>RR 1.16 (0.56 to 2.40)</td>
<td>Study population</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>48 per 1000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>8 more per 1000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(21 fewer to 67 more)</td>
<td></td>
</tr>
</tbody>
</table>

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).*

CI: confidence interval; HR: hazard ratio; MD: mean difference; RCT: randomised controlled trial; RR: risk ratio; SMD: standardised mean difference

**GRADE Working Group grades of evidence.**

- **High certainty**: We are very confident that the true effect lies close to that of the estimate of the effect.
- **Moderate certainty**: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
- **Low certainty**: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
- **Very low certainty**: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

<sup>1</sup>The control event rate at 5 years was based on an overall recurrence rate of 25/58 (43.1%) in the ORC arm reported in **Bochner 2015**

<sup>a</sup>Downgraded by one level for study limitations; risk of performance, detection, and attrition bias.

<sup>b</sup>Downgraded by one level for imprecision: wide confidence intervals consistent with both no effect and clinically important benefit or harm.

<sup>c</sup>Downgraded by one level for study limitations; risk of performance and detection bias.

<sup>d</sup>Downgraded by two levels for very serious imprecision: wide confidence interval consistent with small benefit, no effect, and small harm.

<sup>e</sup>Downgraded by one level for imprecision: wide confidence intervals consistent with both no effect and clinically important reduction in quality of life, assuming SMD of 0.2.
BACKGROUND

Description of the condition

Over 400,000 new cases of bladder cancer are diagnosed annually, accounting for 3% of all cancers (Ferlay 2013; Ferlay 2015; Ploeg 2009). Radical cystectomy (RC) with pelvic lymph node dissection (PLND) and urinary diversion is the gold standard surgical treatment for muscle-invasive bladder cancer (MIBC) (Hayn 2010; Jonsson 2011; Lee 2011; Redorta 2010; Smith 2011; Wirjes 2014). Other indications for RC include high-risk non-muscle-invasive bladder cancer (NMIBC) and recurrent multifocal superficial disease (Hayn 2010; Jonsson 2011; Lee 2011; Redorta 2010; Smith 2011; Wirjes 2014). The procedure has traditionally been performed using an open approach. Morbidity with open radical cystectomy (ORC) is high. In a retrospective review of a prospectively maintained database of 1142 patients who underwent ORC/urinary diversion by high-volume fellowship-trained urological oncologists, the reported 90-day overall complication rate and the 30-day mortality rate were 64% and 1.5%, respectively (Shabsigh 2009).

Description of the intervention

A significant interest in minimally invasive surgery (MIS) has arisen in the last two decades in an attempt to reduce morbidity, expedite recovery, and decrease hospital stay (Hu 2009; Schwenk 2005; Wright 2013). MIS approaches, both conventional laparoscopy and robotic-assisted approaches, have replaced a significant number of open surgical techniques (Hu 2009; Schwenk 2005; Wright 2013). The uptake of conventional laparoscopic radical cystectomy has been impeded by technical challenges associated with the procedure, in particular the reconstructive aspects of the procedure (Aboumarzouk 2012; Aboumarzouk 2013; Castillo 2006; Castillo 2009; Cathelineau 2005; Haber 2008; Hosseini 2011; Huang 2008; Huang 2010; Jonsson 2011; Khan 2011; Sighinolfi 2007; Smith 2011). Robotic-assisted radical cystectomy (RARC)—which offers such advantages as increased manoeuvrability, superior magnification, enhanced EndoWrist® dexterity, and tremor elimination—has been suggested as an alternative to overcome issues associated with the conventional laparoscopic approach (Ishii 2014).

How the intervention might work

Adoption of the robotic approach has been swift in contemporary urological practice, with widespread application of robotic-assisted radical prostatectomy and robotic-assisted partial nephrectomy in Europe and the USA leading to favourable perioperative outcomes in comparison with open and laparoscopic counterparts (Novara 2012). Three systematic reviews of randomised and non-randomised controlled trials suggested shorter operative time and less blood loss for ORC when compared with RARC (Ishii 2014; Novara 2015; Tang 2014). These reviews also demonstrated reduced Clavien grade 3 complications for RARC. Two comparative studies have suggested similar survival outcomes between ORC and RARC (Khan 2012; Nepple 2013).

Why it is important to do this review

Although over 2000 procedures have been reported to the International Robotic Cystectomy Consortium from 37 centres worldwide, well-conducted studies comparing RARCs to ORCs are lacking (Raza 2015). Randomised controlled trials are necessary to establish how RARC compares to ORC. We performed a systematic review to summarise and critically appraise the body of evidence comparing these two approaches to inform clinical decision-making as well as health policy.

OBJECTIVES

To assess the effects of robotic-assisted radical cystectomy versus open radical cystectomy in adults with bladder cancer.

METHODS

Criteria for considering studies for this review

Types of studies

We included all randomised controlled trials (RCTs) and quasi-RCTs of individual participants comparing ORC and RARC. We did not include cluster-randomised trials. We considered all studies regardless of their publication status and language of publication.

Types of participants

We included adult participants with a diagnosis of bladder malignancy who were undergoing radical cystectomy as part of their treatment for pathologically proven MIBC or high-grade NMIBC (T1-4a/carcinoma in situ (CIS), N0M0). We included participants irrespective of histological bladder cancer type (i.e. we included those with urothelial cell carcinoma, squamous cell carcinoma, or adenocarcinoma). We included participants receiving neoadjuvant or adjuvant chemotherapy. We excluded studies of participants with prior radiotherapy in which cystectomy was performed as a salvage procedure.
Types of interventions
We investigated the following comparison of experimental intervention versus comparator intervention. We included trials independent of the urinary diversion method employed. We analysed data by intention-to-treat analysis.

Experimental intervention
Robotic-assisted radical cystectomy.

Comparator intervention
Open radical cystectomy.

Types of outcome measures

Primary outcomes
- Time to recurrence
- Major postoperative complications (class III to V) (Dindo 2004)

Secondary outcomes
- Minor postoperative complications (class I and II) (Dindo 2004)
- Transfusion requirement
- Length of hospital stay (days)
- Quality of life as evaluated via validated participant-reported questionnaire scores or domains reflecting overall or global health of the participant
- Positive margins (%)

Search methods for identification of studies

Electronic searches
We performed a comprehensive search with no restrictions on language of publication nor publication status. We searched the following electronic databases (date of last search was 1 July 2018):
- Cochrane Central Register of Controlled Trials (CENTRAL; latest issue) in the Cochrane library via Wiley
- MEDLINE (1999 to July 2018); PubMed search. We used these terms and medical subject heading (MeSH) phrases: (cystectomy [MeSH terms] AND robotic AND open) AND "surgery" [MeSH subheading]
- EMBASE (1999 to July 2018); Ovid search using the terms cystectomy, open, and robotic
- Web of Science (1999 to July 2018)
- Cancer Research UK (www.cancerresearchuk.org/)
- Institute of Cancer Research (www.icr.ac.uk/)

Data collection and analysis

Selection of studies
Three review authors (BR, OMA, JB) independently assessed relevant titles and abstracts of records identified by the literature search to determine which studies should be assessed further. Three review authors (BR, OMA, JB) investigated all potentially relevant records as full text, mapped records to unique studies, and classified studies as included studies, excluded studies, studies awaiting classification, or ongoing studies, in accordance with the criteria for each provided in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We resolved any disagreement by discussion and consensus or by recourse to a fourth review author (KG). We adapted a PRISMA flow diagram to demonstrate the process of study selection (Liberati 2009).

Data extraction and management
For studies that fulfil inclusion criteria, three review authors (BR, OMA, JB) independently extracted the following information, which is provided in the Characteristics of included studies tables:
- Study design (e.g. parallel-group randomised trial)
- Study dates (if dates were not available, this was reported)
- Study settings and country
- Participant inclusion and exclusion criteria
- Participant details and baseline demographics, such as age and sex
- Numbers of participants by study and by study arm
- Details of relevant experimental and comparator interventions and conversion rates from robotic to open...
Definitions of relevant outcomes and methods and timing of outcome measurement, as well as any relevant subgroups
Study funding sources
Declarations of interest by primary investigators

For dichotomous outcomes, we attempted to obtain numbers of events and totals for populations on a 2 × 2 table, as well as summary statistics with corresponding measures of variance. For continuous outcomes, we attempted to obtain means and standard deviations or data necessary to calculate this information. For time-to-event outcomes, we attempted to obtain hazard ratios (HRs) with corresponding measures of variance or data necessary to calculate this information.

We resolved all disagreements by consensus.

Dealing with duplicate and companion publications
In the event of duplicate publications, companion documents, or multiple reports of a primary study, we maximised the yield of information by mapping all publications to unique studies and collating all available data. We used the most complete data set aggregated across all known publications. In case of doubt, we gave priority to the publication reporting the longest follow-up associated with our primary or secondary outcomes.

Assessment of risk of bias in included studies
Two review authors (BR, OMA) independently assessed the risk of bias of each included study and resolved all disagreements by consensus.

We assessed risk of bias using Cochrane’s ‘Risk of bias’ assessment tool for the following domains (Higgins 2011):
- Random sequence generation (selection bias)
- Allocation concealment (selection bias)
- Blinding of participants and personnel (performance bias)
- Blinding of outcome assessment (detection bias)
- Incomplete outcome data (attrition bias)
- Selective reporting (reporting bias)
- Other sources of bias

For detection bias, we evaluated the risk of bias separately for each outcome. We regarded outcomes such as transfusion requirement and hospital stay as objective, and, if reported, we judged these studies as low risk. If studies did not report these outcomes, we judged them as unclear risk.

For attrition bias, we evaluated risk of bias separately for quality of life. We combined the outcomes major and minor postoperative complications, hospital stay, transfusion requirement, and positive margin rates into a single group for attrition bias.

Measures of treatment effect
We used Review Manager 5 (RevMan 5) (RevMan) to analyse the data. We expressed dichotomous outcomes as risk ratios (RRs) with 95% confidence intervals (CIs). For time-to-event outcomes, we calculated the hazard ratio with 95% CI. We expressed continuous data as mean differences (MDs) or standardised mean differences (SMDs) (if the same outcome was evaluated by different tools) with 95% CIs.

Unit of analysis issues
Parallel-group designs were to be analysed. The unit of analysis was the individual participant. In the event we identified trials with more than two intervention groups for inclusion in the review, we handled these in accordance with guidance provided in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).

Dealing with missing data
When data were missing, we contacted corresponding authors of the trials (Bochner 2015; Nix 2010; Parekh 2013; Parekh 2018). We had received no response from the corresponding authors of individual trials at the time of submission of this review. We imputed missing standard deviations in accordance with guidance provided in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We imputed means and standard deviations from median and range in accordance with guidance provided in Hozo 2005.

Assessment of heterogeneity
In the event of excessive heterogeneity unexplained by subgroup analyses, we did not report outcome results as the pooled effect estimate in a meta-analysis.

We identified heterogeneity by using a Chi² test on N-1 degrees of freedom, with an alpha of 0.05 for statistical significance, and using the I² statistic (Higgins 2003). We interpreted the I² statistic as follows:
- 0% to 40%: may not be important
- 30% to 60%: may indicate moderate heterogeneity
- 50% to 90%: may indicate substantial heterogeneity
- 75% to 100%: indicates considerable heterogeneity

Assessment of reporting biases
We planned to obtain study protocols to evaluate studies for reporting bias. We did not formally perform funnel plot analysis, as the review included only five trials.

Data synthesis
We summarised data using a random-effects model. We interpreted random-effects meta-analyses with due consideration of the whole distribution of effects. In addition, we performed statistical analyses according to the statistical guidelines provided in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).
2011). For dichotomous outcomes, we used the Mantel-Haenszel method; for continuous outcomes, we used the inverse variance method; and for time-to-event outcomes, we used the generic inverse variance method. We used RevMan software to perform analyses.

**GRADE and ‘Summary of findings’ table**

We presented the overall quality of evidence for each outcome according to the GRADE approach, which takes into account five criteria related not only to internal validity (risk of bias, inconsistency, imprecision, publication bias), but also to external validity, such as directness of results (Guyatt 2008). Two review authors (BR, OMA) independently rated the quality of evidence for each outcome as ‘high’, ‘moderate’, ‘low’, or ‘very low’, using GRADEpro GDT. We resolved any discrepancies by consensus.

We presented a summary of evidence for the main outcomes in a ‘Summary of findings’ table, which provides key information about the best estimate of the magnitude of effect in relative terms and absolute differences for each relevant comparison of alternative management strategies; numbers of participants and studies addressing each important outcome; and the rating of overall confidence in effect estimates for each outcome (Guyatt 2011).

**Main outcomes for ‘Summary of findings’ table**

We have presented a ‘Summary of findings’ table to report the following outcomes listed according to priority:

- Time to recurrence
- Major postoperative complications (class III to V) (Dindo 2004)
- Minor postoperative complications (class I and II) (Dindo 2004)
- Length of hospital stay (days)
- Quality of life
- Positive margins (%)

**Subgroup analysis and investigation of heterogeneity**

We attempted to perform subgroup analyses to explore possible sources of heterogeneity. We considered the following subgroups:

- Participant age (younger than 60 years vs 60 years of age and older)
- Participant body mass index (< 30 kg/m² vs ≥ 30 kg/m²)
- Pathological stage (≤ pT2 disease vs pT3 disease)
- Surgeon’s level of experience (less than expert vs expert, as defined by trial authors)

We planned to test for subgroup differences using RevMan 5 to compare subgroup analyses if we found sufficient studies (RevMan). We could not do this with the information provided in the included studies.

**RESULTS**

**Description of studies**

We identified 332 references through electronic searches of the different databases. We retrieved a total of 32 references for further detailed assessment. We excluded 26 references for the reasons listed in the Characteristics of excluded studies table. We found that seven references on five randomised controlled trials (RCTs) fulfilled the review inclusion criteria (see Characteristics of included studies). Two trials published outcomes in two separate publications (Bochner 2015; Parekh 2013). We have presented the reference flow in Figure 1.
Figure 1. Study flow diagram.

Literature Search Number = 332

216 articles excluded after screening of titles

116 of records screened (potential articles for evaluation of abstracts)

84 articles excluded after screening of abstracts

32 full-text articles assessed for eligibility

26 full-text articles excluded (all non-randomized trials)

5 studies included in quantitative synthesis (meta-analysis)
Included studies

Study design and setting
Five trials were published between 2010 and 2018:
- Nix 2010 reported the first trial of RARC versus ORC. Researchers conducted this study at the University of North Carolina in the USA and randomised 21 participants to an open approach and 20 to a robotic-assisted laparoscopic approach. The study had no noninferiority design, and its primary outcome was lymph node yield.
- The RAZOR trial (a prospective, multicentre, randomised trial of open vs robotic radical cystectomy) was the largest and most recently published trial (Parekh 2018). It was conducted at 15 academic centres in the USA and randomised 159 and 153 participants to RARC and ORC cohorts, respectively (Parekh 2018). After exclusions, 150 participants were included in the RARC cohort and 152 participants in the ORC cohort, in the per-protocol analysis set (Parekh 2018). The study used a noninferiority design and included a primary outcome of progression-free survival at two years.
- Parekh 2013 reported the results of a preceding pilot trial leading up to the RAZOR trial that was conducted at the University of Texas at San Antonio in the USA. Study authors randomised 20 participants each to RARC and ORC and reported oncological outcomes and quality of life outcomes - in two separate publications (Parekh 2013). This study had no specific primary endpoint aside from establishing randomisation.
- Bochner 2015 reported the results of a single-institution, randomised trial conducted at Memorial Sloan Kettering Cancer Center in the USA. Investigators randomised 60 and 58 participants to RARC and ORC cohorts, respectively. The study was described as an expertise-based trial. Study authors reported oncological outcomes in a second publication.
- Khan 2016 reported the results of a single-institution, three-armed, randomised trial conducted at Guy’s Hospital, in London, United Kingdom, that randomised 20 participants each to RARC, ORC, and (pure) laparoscopic cystectomy. This study was described as an expertise-based trial.

Participants
The total numbers of participants included in the ORC and RARC cohorts were 270 and 271, respectively. Most participants in both the ORC (221; 82%) and RARC (226; 83.4%) groups were men. Three studies reported demographic data using the median (Bochner 2015; Parekh 2013; Parekh 2018) and two using the mean (Khan 2016; Nix 2010). The mean age of participants in the ORC cohort ranged between 66.6 years and 69.2 years. The mean age of participants in the RARC cohort ranged between 67.4 years and 68.6 years. The median age of participants in the ORC cohort ranged between 64.5 years and 65 years. The median age of participants in the RARC cohort ranged between 66 years and 69.5 years. The mean body mass index (BMI) (in kg/m²) of participants in the ORC cohort ranged between 27.4 and 28.4. The mean BMI (kg/m²) of participants in the RARC cohort ranged similar at 27.5. The median BMI (kg/m²) of participants in the ORC cohort ranged between 24.9 and 31.7, and the median BMI (kg/m²) of participants in the RARC cohort ranged between 25 and 30.8.

Interventions and comparators
All five studies compared ORC to RARC (Bochner 2015; Khan 2016; Nix 2010; Parekh 2013; Parekh 2018); one trial included an arm of laparoscopic radical cystectomy (Khan 2016). Four studies performed urinary diversion extracorporeally (Bochner 2015; Khan 2016; Nix 2010; Parekh 2018). One study performed urinary diversion at the discretion of the surgeon and did not explicitly report the type (Parekh 2013). In the ORC cohort, urinary diversion was ileal conduit, neobladder, and continent cutaneous type in 194 (72%), 73 (27%), and 3 (1%) participants, respectively. In the RARC cohort, urinary diversion was ileal conduit, neobladder, and continent cutaneous type in 191 (70.6%), 79 (29%), and 1 (0.4%) participant, respectively. All five trials performed a pelvic lymph node dissection (Bochner 2015; Khan 2016; Nix 2010; Parekh 2013; Parekh 2018). We have summarised the inclusion criteria for each study in the Characteristics of included studies table.

Outcomes
Bochner 2015 reported on patient-reported outcomes (PROs) of quality of life (QoL) using the validated European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) survey. Khan 2016 evaluated QoL using the validated Functional Assessment of Cancer Therapy (FACT) v4 questionnaire. Parekh 2013 and Parekh 2018 evaluated QoL using the validated Functional Assessment of Cancer Therapy - Bladder (FACT-Bl) scale v4 questionnaire. Parekh 2013 and Parekh 2018 evaluated QoL using the validated Functional Assessment of Cancer Therapy - Vanderbilt Cystectomy Index (FACT-VCI) questionnaire.

Funding
Parekh 2018 was funded by the National Institutes of Health National Cancer Institute.
Bochner 2015 was supported by the Sidney Kimmel Center for Prostate and Urologic Cancers at Memorial Sloan Kettering Cancer Center, Pin Down Bladder Cancer, and the Michael and Zena
Wienerfor Therapeutics Program in Bladder Cancer. Study sponsors were involved in the design and conduct of the study; in collection, analysis, management, and interpretation of the data; and in preparation, review, and approval of the manuscript. Khan 2016 was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St. Thomas’ NHS Foundation Trust and King’s College London. Study authors acknowledge support from the NIHR Biomedical Research Centre, the Medical Research Council Centre for Transplantation, King’s Health Partners, Guy’s and St. Thomas’ Charity, the School of Surgery, the London Deanery, the Royal College of Surgeons of England, Intuitive Surgical, the Urology Foundation, Olympus, EU-FP7, ProstateCancer UK, the Technology Strategy Board, and the Vattikuti Foundation. The remaining two studies did not report funding (Nix 2010; Parekh 2013).

Excluded studies
We excluded 26 of these publications. All of these studies were nonrandomised comparative studies comparing ORC and RARC (Excluded studies). We have documented further details of individual studies in the Characteristics of excluded studies table.

Risk of bias in included studies
We have summarised the methodology and risk of bias of individual trials in the Characteristics of included studies table. We have summarised the risk of bias for individual trials in Figure 2.
Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included study.
Allocation

Random sequence generation
We judged all five trials to have low risk of bias for random sequence allocation (Bochner 2015; Khan 2016; Nix 2010; Parekh 2013; Parekh 2018).

Allocation concealment
Nix 2010 performed a randomisation schema with five sequential participants undergoing one approach before alternating with another approach. Their concealment would have to be deemed inadequate and hence judged to be at high risk of bias. The remaining trials had low risk of bias in their allocation concealment strategy (Bochner 2015; Khan 2016; Parekh 2013; Parekh 2018).

Blinding

Performance bias
Due to the nature of the intervention (RARC vs ORC), it is considered unlikely that participants or personnel were blinded for any of the review outcomes. We therefore judged all included studies to be at high risk of performance bias.

Detection bias

Time to recurrence
Two trials reported on recurrence-free survival (Bochner 2015; Parekh 2018). Due to the lack of blinding of outcome assessors, we judged Parekh 2018 to be at high risk of detection bias for recurrence-free survival (Parekh 2018). We judged one trial as having unclear risk of detection bias for recurrence-free survival, as trial authors did not explicitly state who assessed this outcome (Bochner 2015).

Complications (all grades)
Three included studies were unblinded; we therefore judged them to be at high risk of detection bias for complications (Bochner 2015; Khan 2016; Parekh 2018). Two studies did not report who the assessors were and whether blinding had taken place; hence we judged them to be at unclear risk of detection bias for complications (Nix 2010; Parekh 2013).

Quality of life
In all four included studies, participants were not blinded; we therefore judged these trials to be at high risk of detection bias for the self-assessed outcome of quality of life survey (Bochner 2015; Khan 2016; Parekh 2013; Parekh 2018). One study did not report quality of life data (Nix 2010).

Positive margin rates, hospital stay, and transfusion rates
The review authors opined that positive margin rates, hospital stay, and transfusion rates were unlikely to be affected by the blinding status of outcome assessors in these trials. We therefore judged all five studies to be at low risk of detection bias for positive surgical margin rates and hospital stay (Bochner 2015; Khan 2016; Nix 2010; Parekh 2013; Parekh 2018). Nix 2010, Bochner 2015, and Khan 2016 did not report on transfusion rates. We judged Parekh 2018 and Parekh 2013 to be at low risk of detection bias for transfusion rates.

Incomplete outcome data

Quality of life
We judged four studies to be at high risk of attrition bias for quality of life survey results, given that a large proportion of participants (>20%) failed to provide information (Bochner 2015; Khan 2016; Parekh 2013; Parekh 2018).

Major and minor postoperative complications, transfusion requirements, hospital stay, and positive margins
We rated all studies as having low risk of attrition bias with near complete inclusion of randomised participants in analyses for these outcomes (Bochner 2015; Khan 2016; Nix 2010; Parekh 2013; Parekh 2018).

Time to recurrence
We rated Bochner 2015 as having low risk of attrition bias, with all randomised participants included in the analysis. We rated Parekh 2018 as having unclear risk of attrition bias.

Selective reporting
Four studies had protocols registered in a trials registry (Bochner 2015; Khan 2016; Parekh 2013; Parekh 2018). We noted no obvious selective reporting for the outcomes of this review in these studies, and hence we judged them as having low risk of reporting
bias. We were unable to find a protocol for the Nix 2010 trial. Therefore, we judged this trial as having an unclear risk of reporting bias.

Other potential sources of bias
We identified no other biases in any of the other included trials (Bochner 2015; Khan 2016; Nix 2010; Parekh 2013; Parekh 2018).

Effects of interventions
See: Summary of findings for the main comparison Robotic-assisted laparoscopic vs open radical cystectomy for bladder cancer in adults

Primary outcomes

Time to recurrence
RARC may result in a similar time to recurrence as ORC (hazard ratio (HR) 1.05, 95% confidence interval (CI) 0.77 to 1.43); 2 trials; low-certainty evidence) (Figure 3). We downgraded the certainty of evidence for study limitations and imprecision (Analysis 1.1; Summary of findings for the main comparison). In absolute terms, this corresponds to 16 more recurrences per 1000 participants (95% CI 79 fewer to 123 more). The control event rate at 5 years was based on an overall recurrence rate of 25/58 (43.1%) in the ORC arm reported in Bochner 2015.

Figure 3. Forest plot of comparison: I Primary Outcome, outcome: 1.1 Recurrence-Free Survival.

Major complications (Clavien grades 3 to 5)
RARC may result in similar rates of major complications as ORC (risk ratio (RR) 1.06, 95% CI 0.76 to 1.48); 5 trials; low-certainty evidence) (Figure 4). This corresponds to 11 more major complications per 1000 participants (95% CI 44 fewer to 89 more). We downgraded the certainty of evidence for study limitations and imprecision (Analysis 1.2; Summary of findings for the main comparison).
Five trials reported on complications. Three studies reported the total number of Clavien grade 3 to 5 complications (Bochner 2015; Khan 2016; Parekh 2018). The other two studies reported specific complications (Nix 2010; Parekh 2013), based on which the review authors were able to classify complications by adopting the Clavien-Dindo grading system (Dindo 2004).

### Secondary outcomes

#### Minor complications (Clavien grades 1 and 2)

We are very uncertain whether RARC results in fewer minor complications than ORC (RR 0.82, 95% CI 0.58 to 1.17; 4 trials; very low-certainty evidence). This corresponds to 80 fewer minor complications per 1000 participants (95% CI 186 fewer to 75 more). We downgraded the certainty of evidence for serious study limitations and very serious imprecision (Analysis 1.3; Summary of findings for the main comparison).

#### Transfusion rate

RARC probably results in fewer transfusions than ORC (RR 0.58, 95% CI 0.43 to 0.80; 2 trials; moderate-certainty evidence). This corresponds to 193 fewer transfusions per 1000 participants (95% CI 262 fewer to 92 fewer). We downgraded the certainty of evidence for study limitations and imprecision (Analysis 1.4; Summary of findings for the main comparison). Only two studies reported on transfusion rates (Parekh 2013; Parekh 2018).

#### Length of hospital stay (days)

All five trials provided information on hospital stay. One trial reported similar mean hospital stays of 5.1 days and 6 days in the RARC and ORC cohorts but did not report a standard deviation (Nix 2010). We therefore imputed the standard deviation. Two trials reported hospital stay in median and range values (Parekh 2013; Parekh 2018). We therefore imputed the mean and standard deviation for these trials. Two studies provided explicit data on mean hospital stay for meta-analysis (Bochner 2015; Khan 2016). Overall, we found that RARC may reduce mean hospital stay slightly (mean difference (MD) -0.67, 95% CI -1.22 to -0.12; 5 trials; low-certainty evidence). We downgraded the quality of evidence for study limitations and imprecision (Analysis 1.5; Summary of findings for the main comparison).

#### Quality of life

RARC may result in similar quality of life when compared with ORC (standard mean difference (SMD) 0.08, 95% CI 0.32 lower to 0.16 higher; 3 trials; low-certainty evidence). We downgraded the certainty of evidence for study limitations and imprecision (Analysis 1.6; Summary of findings for the main comparison). Four studies reported on quality of life (QoL) outcomes (Bochner 2015; Khan 2016; Parekh 2013; Parekh 2018). One trial used the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) survey (Bochner 2015). In this trial, data from the Global Health status domain were used for analysis, as this information reflected overall health status. One trial used the Functional Assessment of Cancer Therapy -Bladder (FACT-BL) scale v4 and covered phys-
ical, emotional, and social well-being, as well as questions specific to bladder cancer (Khan 2016). Two trials used the Functional Assessment of Cancer Therapy -Vanderbilt Cystectomy Index (FACT-VCI) questionnaire (Parekh 2013; Parekh 2018). The standardised mean difference was used in view of the different QoL assessment tools used. One study reported QoL in median and range values (Parekh 2013). We therefore imputed mean and standard deviation for this study.

**Positive margin rates**

RARC may result in similar positive margin rates when compared to ORC (RR 1.16, 95% CI 0.56 to 2.40; 5 trials; low-certainty evidence). This corresponds to eight more positive margins per 1000 participants (95% CI 21 fewer to 67 more).

We downgraded the certainty of evidence for study limitations and imprecision (Analysis 1.7; Summary of findings for the main comparison).

We were unable to conduct any of the preplanned secondary analyses due to lack of suitable data.

**DISCUSSION**

**Summary of main results**

There may be little to no difference in time to recurrence and in risk of major complications between the two surgical approaches to treat muscle-invasive bladder cancer. We are very uncertain whether RARC reduces the rate of minor complications. There may be little to no difference in quality of life and positive margin rates. RARC probably reduces transfusions substantially and may reduce length of stay slightly.

**Overall completeness and applicability of evidence**

Follow-up of the included trials is generally limited; only one trial has reported longer-term follow-up for the outcome of recurrence-free survival at a median follow-up of 4.9 years (Bochner 2015). Another trial reported on progression-free survival at two years (Parekh 2018). Review authors judged this trial to have high risk of performance and detection bias for recurrence-free survival. One small trial provided data on recurrence rates and overall and disease-specific mortality at 12 months (Khan 2016). We judged this trial to have high risk of performance, detection, attrition, and reporting bias. Follow-up was very short, at 12 months, further emphasising the lack of vital long-term oncological data derived from randomised controlled trials (RCTs) comparing open radical cystectomy (ORC) and robotic-assisted radical cystectomy (RARC).

All studies reported on complication rates. However, two studies did not demonstrate clear categorisation into minor and major complications using the Clavien-Dindo grading system, as suggested by this review (Nix 2010; Parekh 2013). We therefore examined individual complications reported by these trials and classified them using the Clavien-Dindo grading system. Although data show no obvious differences between ORC and RARC for major complications, the outcomes again were of low quality, suggesting significant uncertainty of the results, and hence must be viewed with caution.

For the outcomes “hospital stay” and “quality of life”, three studies reported unfavourable metrics and statistical methods (e.g. median, no standard deviations reported for means) for meta-analysis (Nix 2010; Parekh 2013, Parekh 2018). The review authors therefore imputed these data.

**Quality of the evidence**

We rated the certainty of evidence as low for all outcomes, except transfusion rates and hospital stay. We consistently downgraded evidence for a combination of study limitations, most often performance bias (lack of blinding of participants and personnel) and detection bias (lack of blinding of outcome assessors). We also frequently downgraded evidence for imprecision due to wide confidence intervals that indicated no effect but also included the possibility of clinically relevant benefit or harm.

**Potential biases in the review process**

We performed this systematic review in accordance with current Cochrane standards. The review nevertheless has the following limitations:

- The review authors cannot be absolutely certain if we missed identifying any other potential randomised trials comparing ORC and RARC in our search, although we think this is unlikely.
- We excluded from the meta-analysis some of the data reported by individual studies due to lack of appropriate data points. We contacted the authors of these individual studies but were not successful in obtaining additional data. We chose to impute data in accordance with the editorial policy of Cochrane standards.

**Agreements and disagreements with other studies or reviews**

We identified five relevant systematic reviews of randomised and nonrandomised controlled trials comparing robotic and open radical cystectomy (Ishii 2014; Novara 2015; Tang 2014; Yuh 2015; Sathianathen 2018). These reviews used pooled data derived across
all study designs, and none considered evaluation of the quality of evidence as defined by GRADE.

Yuh 2015 performed a cumulative analysis of oncological and functional outcomes of robotic-assisted radical cystectomy (RARC). This review identified 65 surgical series and 22 comparative studies reporting on pathological, oncological, and functional outcomes of RARC. Two trials in the review were randomised trials (Nix 2010; Parekh 2013). We included both of these studies in our review. A majority of the studies included in this review were retrospective studies. No certainty of evidence was assessed. The review identified two nonrandomised comparative studies that reported similar survival outcomes between ORC and RARC (Khan 2012; Nepple 2013). Review authors suggested caution when interpreting these results due to short follow-up, small series, and study limitations.

Novara 2015 performed a cumulative analysis of perioperative outcomes and postoperative complications of RARC. This review identified 70 surgical series and 23 comparative studies. Three trials included in the review were randomised trials (Bochner 2015; Nix 2010; Parekh 2013). We have included these three studies in our review. A majority of studies included in the Novara review were retrospective studies. Review authors categorised individual studies to the 2011 level of evidence and IDEAL recommendations and scrutinised the quality of reporting of complications of individual studies using the Martin criteria (Martin 2002). They performed no other quality assessment of individual studies. These review authors reported 90-day complication rates of any grade and found that 90-day grade 3 complication rates were lower for RARC, whereas high-grade complication and mortality rates were similar. It is unclear from the review how the review authors differentiated between grade 3 complications and high-grade complications. The analysis for grade 3 complications did not include any of the RCTs. The analysis for high-grade complications included one RCT (Bochner 2015). The RCT included in this analysis contributed 19.3% to the study weight.

Tang 2014 performed a systematic review that included 13 studies comparing RARC and ORC. One trial in the review was a randomised trial (Nix 2010). We have included this study in our review. These review authors reported perioperative and pathological outcomes and complications. Review authors pooled data across all study designs. They rated the level of evidence (LOE) of included studies according to criteria provided by the Centre for Evidence-Based Medicine in Oxford, UK. They assessed risk of bias of the RCT using the Jadad scale and of observational studies using the Newcastle-Ottawa scale. Pooled analysis favoured the RARC cohort for overall complication rate. Nix 2010, the only RCT included in the analysis, contributed only 5.5% to the study weight.

Ishii 2014 performed a systematic review that included seven studies comparing RARC and ORC. Two trials in the review were randomised trials (Nix 2010; Parekh 2013). We have included both of these studies in our review. Review authors assessed the methodological quality of these included studies in line with the Cochrane Handbook for Systematic Reviews of Interventions. The primary outcome of this study was complication rates. Pooled analysis favoured the RARC cohort for major complication rates. Analysis for major complications included one RCT (Parekh 2013), which contributed to 6.7% to the study weight.

Sarthianathan 2018 has published the most recent and highest-quality review to date. Methodological hallmarks include an a priori registered protocol with predefined primary outcomes, a comprehensive search of multiple data sources, and study inclusion irrespective of language of publication status and use of GRADE to assess the quality of evidence on a per-outcome basis. Instead of recurrence-free survival as a time-to-event outcome used in our review, these review authors analysed risk of recurrence as a dichotomous outcome. They rated findings as moderate-quality evidence, which is more optimistic than our rating of low-quality evidence, while qualifying that there is little to no difference between the two approaches. What our review further adds is a summary of findings table (Summary of findings for the main comparison) with corresponding absolute effect size estimates.

**AUTHORS’ CONCLUSIONS**

**Implications for practice**

Based on the findings of this review, oncological outcomes and rates of major complications may be similar for both approaches. Robotic-assisted cystectomy probably reduces transfusion needs substantially and may slightly reduce length of hospital stay. We are uncertain whether minor complications are also reduced. We were unable to address how patients’ and surgeons’ characteristics may affect these outcomes. Furthermore, this review was not designed to address resource utilisation or cost-effectiveness.

**Implications for research**

This review is based on five relatively small trials with methodological limitations that provided low-quality evidence for most outcomes. Only one trial has provided long-term oncological outcomes (Bochner 2015). We see the following research needs:

- Investigators of existing trials should report longer-term results for longer-term oncological outcomes.
- Researchers should assess the influence of patient factors such as pathological stage and body habitus.
- Studies should establish the impact of surgeon factors such as skills and experience on outcomes.
- Most instances of urinary diversion reported in included trials were performed through an extracorporeal approach. Future trials should evaluate outcomes between open radical...
cystectomy and robotic-assisted radical cystectomy performed through intracorporeal urinary diversions.

- Any future trial should apply widely accepted methodological safeguards against bias and should transparently report them.

**ACKNOWLEDGEMENTS**

We would like to thank the editors of Cochrane Urology for the support they provided.

**REFERENCES**

References to studies included in this review

Bochner 2015  


Khan 2016  

Nix 2010  

Parekh 2013  


Parekh 2018  

References to studies excluded from this review

Anderson 2013  

Atmaca 2015  

Bak 2016  

Borza 2017  

Cusano 2016  
Cusano A, Haddock P Jr, Jackson M, Staff J, Wagner J, Meraney A. A comparison of preliminary oncologic outcome and postoperative complications between patients undergoing either open or robotic radical cystectomy. *International Brazilian Journal of Urology* 2016;42(4):663–70. PUBMED: 27564275

Galich 2006  
Galich A, Sterrett S, Nazemi T, Pohlman G, Smith L, Balaji KC. Comparative analysis of early perioperative outcomes

**Robotic versus open radical cystectomy for bladder cancer in adults (Review)**

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Robotic versus open radical cystectomy for bladder cancer in adults (Review)

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

following radical cystectomy by either the robotic or open method. Journal of the Society of Laparoendoscopic Surgeons 2006;10(2):145–50.

Gandaglia 2016 (published data only)

Ginot 2016 (published data only)

Gondo 2012 (published data only)

Khan 2012 (published data only)

Koupparis 2015 (published data only)

Lee 2011 (published data only)

Li 2016 (published data only)

Martin 2011 (published data only)

Matulewicz 2016 (published data only)
Matulewicz RS, DeLancey JO, Manjunath A, Tse J, Kundu SD, Meeks JJ. National comparison of oncologic quality indicators between open and robotic-assisted radical cystectomy. Urologic Oncology 2016;34(10):431.e9–431.e15. PUBLMED: 27264169

Musch 2014 (published data only)

Neppe 2013 (published data only)

Ng 2010 (published data only)

Nguyen 2015 (published data only)

Rhee 2006 (published data only)

Satkunasivam 2016 (published data only)

Sharma 2017 (published data only)

Stryn 2012 (published data only)

Tan 2016 (published data only)

Wang 2008 (published data only)
Winters 2016  *(published data only)*

**References to ongoing studies**

Kelly , Catto 2017  *(published data only)*

**Additional references**

Aboumarzouk 2012

Aboumarzouk 2013

Ballantyne 2003

Castillo 2006

Castillo 2009

Cathelineau 2005

Dindo 2004

Ferlay 2013

Ferlay 2015

**GRADEpro GDT**

Guyatt 2008

Guyatt 2011

Haber 2008

Hayn 2010

Higgins 2003

Higgins 2011

Hosseini 2011

Hozo 2005
Hu 2009

Huang 2008

Huang 2010

Ishii 2014

Jonsson 2011

Khan 2011

Liberati 2009

Martin 2002

Novara 2012

Novara 2015

Ploeg 2009

Raza 2015

Redorta 2010

RevMan [Computer program]

Sathianathen 2018

Schwenk 2005

Shabsigh 2009

Sighinolfi 2007

Smith 2011

Tang 2014

Wijte 2014
Wijte JA, Comperat E, Cowan NC, De Santis M, Gakis G, Lehret T, et al. EAU guidelines on muscle-invasive and

Wright 2013

Yuh 2015

* Indicates the major publication for the study
## Characteristics of included studies  [ordered by study ID]

### Bochner 2015

<table>
<thead>
<tr>
<th><strong>Methods</strong></th>
<th><strong>Characteristics</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Study design: parallel RCT, expertise-based, superiority trial</td>
<td>● Study hypothesised that the rate of Clavien grade 2 to 5 complications would be 20% lower in absolute terms for RARC compared with ORC. This trial with an α of 5% and 80% power would require 93 participants per arm. However, due to a mandated interim analysis to occur halfway through enrolment, the study intended to accrue 105 participants per arm to maintain 80% power. For the interim analysis, study authors would calculate the upper bound of a one-sided 95% CI for the difference in rate of Clavien grade 2 to 5 complications between surgery groups. If the upper bound was 20%, they would stop the trial for futility.</td>
</tr>
<tr>
<td>Study date: March 2010 to March 2013</td>
<td></td>
</tr>
<tr>
<td>Study setting: hospital-based, single-institution study - Memorial Sloan Kettering Cancer Center (MSKCC), USA</td>
<td></td>
</tr>
<tr>
<td>Randomisation ratio: 1:1</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Participants</strong></th>
<th><strong>Characteristics</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults undergoing radical cystectomy (n = 118)</td>
<td>● Bladder cancer with clinical stage Tₐ-T₃/N₀-₃/M₀</td>
</tr>
<tr>
<td>Diagnostic criteria:</td>
<td>● Medically cleared for RC plus PLND</td>
</tr>
<tr>
<td>Inclusion criteria:</td>
<td>● Aged 18 years</td>
</tr>
<tr>
<td>Exclusion criteria:</td>
<td>● Clinical stage T₄ or M₁</td>
</tr>
<tr>
<td></td>
<td>● Any contraindication for Trendelenburg position, or extensive prior abdominal surgery</td>
</tr>
<tr>
<td>Demographic data: RARC vs ORC</td>
<td>Median age years (IQR) = 66 (60 to 71) vs 65 (58 to 69)</td>
</tr>
<tr>
<td></td>
<td>Male sex, n (%) = 51 (85) vs 42 (72)</td>
</tr>
<tr>
<td></td>
<td>Body mass index, kg/m², median (IQR) = 27.9 (24.7 to 31.0) vs 29.0 (26.3 to 33.7)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Interventions</strong></th>
<th><strong>Characteristics</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cohort 1 = ORC with urinary diversion and PLND (n = 58)</td>
<td>● Men underwent removal of the prostate if present, and women underwent hysterectomy and bilateral salpingo-oophorectomy if organs were present.</td>
</tr>
<tr>
<td>Cohort 2 = RARC with extracorporeal urinary diversion and PLND (n = 60)</td>
<td>● <strong>Lymphadenectomy template:</strong> The extent of the PLND was left to the discretion of the surgeon based on clinician preference and judgement (extent of disease, vascular disease) and was determined before randomisation. The extent of PLND was alterable intraoperatively based on clinical findings (vascular disease, fibrosis, adenopathy).</td>
</tr>
<tr>
<td></td>
<td>● <strong>Surgeon experience:</strong> This is an expertise-based study. All RARC procedures were performed by 1 of 3 surgeons with extensive robotic pelvic surgery experience. All urinary diversions were performed as open surgeries; therefore, 1 of the surgeons experienced in open procedures completed them, regardless of the randomisation arm. All surgeons were urological oncology fellowship trained and had a minimum of 10 years’ experience.</td>
</tr>
<tr>
<td>Years’ operative experience in practice after fellowship.</td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>- Number of conversions from RARC to ORC: 0</td>
<td></td>
</tr>
<tr>
<td>- Number of participant crossovers to ORC after randomising to RARC: 4</td>
<td></td>
</tr>
<tr>
<td>(patient refusal to have RARC)</td>
<td></td>
</tr>
</tbody>
</table>

**Outcomes**

- Primary outcomes
  - Overall 90-day grade 2 to 5 complications defined by a modified Clavien system
- Secondary outcomes included
  - Comparison of high-grade complications
  - Estimated blood loss
  - Operative time
  - Pathological outcomes
  - 3- and 6-month patient-reported QoL outcomes
  - Total operative room and inpatient costs
- ITT analysis performed

**Funding sources**

This study was supported by the Sidney Kimmel Center for Prostate and Urologic Cancers at Memorial Sloan Kettering Cancer Center, Pin Down Bladder Cancer, and the Michael and Zena Wienerfor Therapeutics Program in Bladder Cancer. Study sponsors were involved in the design and conduct of the study; in collection, analysis, management, and interpretation of the data; and in preparation, review, and approval of the manuscript.

**Declarations of interest**

None

**Notes**

Language of publication: English

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td><strong>Quote from publication:</strong> “Consenting patients were stratified by age (64 vs 65 yr) and American Society of Anesthesiologists score (1-2 vs 3-4), then randomly assigned 1:1 to undergo RARC or ORC using randomly permuted blocks of random length.” <strong>Comment:</strong> adequate random sequence generation performed</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td><strong>Quote from publication:</strong> “Randomization was conducted by an independent office, where allocation concealment was ensured by a password-protected database, such that the randomization group could not be predicted prior to receiving group assignment and group could not be changed after randomization.”</td>
</tr>
</tbody>
</table>

Robotic versus open radical cystectomy for bladder cancer in adults (Review)

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Risk Level</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td><strong>Comment:</strong> adequate allocation concealment</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Recurrence Free Survival</td>
<td>Unclear risk</td>
<td><strong>Comment:</strong> Trial does not explicitly state who collected these data.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) QOL</td>
<td>High risk</td>
<td><strong>Comment:</strong> participant-reported outcomes; participants not blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Complications</td>
<td>High risk</td>
<td><strong>Quote from publication:</strong> “All complications were graded on the MSKCC modified Clavien grading scale. Complications data were collected prospectively by unblinded MSKCC research study staff at the initial postoperative, 3-mo, and 6-mo follow-up visits using the institution's standard reporting method for postoperative complications.” <strong>Comment:</strong> assessor unblinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Transfusion Rates</td>
<td>Unclear risk</td>
<td><strong>Comment:</strong> not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Hospital Stay</td>
<td>Low risk</td>
<td><strong>Comment:</strong> unlikely to be affected by non-blinding</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Positive Margin Rates</td>
<td>Low risk</td>
<td><strong>Quote from publication:</strong> &quot;All pathologic specimens were reviewed blinded to surgical technique.” <strong>Comment:</strong> adequate blinding; additionally, regardless of blinding, low risk of detection bias</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Complications/Transfusion/Hospital Stay/Positive Margins</td>
<td>Low risk</td>
<td><strong>Comment:</strong> All randomised participants were included in the analysis for these outcomes</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) QOL</td>
<td>High risk</td>
<td><strong>Quote from publication:</strong> ”Fifty-eight patients returned evaluable baseline surveys and 53 returned follow-up surveys at 3 and 6 mo.” <strong>Comment:</strong> In the RARC group, 60 par-</td>
</tr>
</tbody>
</table>
### Bochner 2015  (Continued)

| Incomplete outcome data (attrition bias) | Low risk | **Comment:** All randomised participants were included in the analysis. |
| Recurrence Free Survival |  |

| Selective reporting (reporting bias) | Low risk | All predefined outcomes were reported for both groups in the time period suggested. |
| Other bias | Low risk | **Comment:** not detected |

### Khan 2016

#### Methods
- Study design: randomised controlled 3-arm parallel-group, expertise-based, superiority trial
- Study date: March 2009 to July 2012
- Study setting: hospital setting - Guy’s Hospital, London, UK
- Study authors estimated the RARC complication rate as 10% to 15% and the ORC complication rate as 25% to 60%. Therefore, the number needed in each arm ranges from 43 to 58, so the 95% CI for the estimated difference in rates is 16%. Based on these considerations, researchers aimed to recruit 47 participants per arm. A 3-year interim analysis suggests no significant differences in primary outcomes between arms, and, coupled with recruitment difficulties, the institutional research project steering board recommended terminating the trial at that point.

#### Participants

**Adults undergoing radical cystectomy (n = 60)**

**Diagnostic criteria:**
- MIBC and high-risk NMIBC

**Inclusion criteria:**
- Participants between 18 and 80 years of age requiring RC for MIBC or high-risk NMIBC

**Exclusion criteria:**
- Unsuitable for laparoscopic radical cystectomy or robotic-assisted radical cystectomy due to severe cardiopulmonary comorbidities
- Extensive abdominopelvic surgery or radiation

**Demographic data: RARC vs ORC**
- Mean age years (SD) = 68.6 (6.8) vs 66.6 (8.8)
- Male sex, n (%) = 17 (85) vs 18 (90)
- Body mass index, kg/m², mean (SD) = 27.5 (4.2) vs 27.4 (3.9)

#### Interventions
- **Cohort 1 = ORC with urinary diversion and PLND (n = 20)**
- **Cohort 2 = RARC with extracorporeal urinary diversion and PLND (n = 20)**
- **Cohort 3 = LRC with extracorporeal urinary diversion and PLND (n = 20)**
- All neo-bladders were fashioned using the Studer technique.
- **Lymphadenectomy template:** obturator, external/internal/common iliac, and presacral nodes
Khan 2016  (Continued)

- **Surgeon experience**: This is an expertise-based study. At trial initiation, the ORC surgeon had performed > 150 ORCs and the RARC surgeon had performed 110 RARCs.
- **Number of conversions from RARC to ORC**: 0
- **Number of participant cross-overs to ORC after randomising to RARC**: 1 (equipment failure)

### Outcomes

- **Primary end points**
  - 30- and 90-day complication rates
- **Secondary end points**
  - Perioperative parameters (operative time, EBL, delay in bowel function, and LOS)
  - Pathological outcomes (margin status and number of lymph nodes retrieved)
  - 12-month oncological outcomes
  - QoL - study authors do not state in the methodology when they plan to assess

### Funding sources

The research, including statistical support (Jennifer A. Summers and Janet L. Peacock), was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre, based at Guy’s and St. Thomas' NHS Foundation Trust and King's College London. Prokar Dasgupta and Kamran Ahmed acknowledge support from the NIHR Biomedical Research Centre, Medical Research Council Centre for Transplantation, King's Health Partners, Guy's and St. Thomas' Charity, School of Surgery, London Deanery, Royal College of Surgeons of England, Intuitive Surgical, The Urology Foundation, Olympus, EU-FP7, ProstateCancer UK, Technology Strategy Board, and The Vattikuti Foundation.

### Declarations of interest

None

### Notes

Language of publication: English

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td><strong>Quote from publication</strong>: “Randomisation was undertaken by the trial nurse (J.W.) using identical sealed opaque envelopes, each containing a piece of paper designating the surgical modality (ORC, LRC, or RARC). Simple randomisation was performed in two groups of 30. In each group, each modality was allocated 10 envelopes. These were shuffled and then numbered 1-30. Patients received the next envelope in numerical order.” <strong>Comment</strong>: random sequence generation adequate</td>
</tr>
</tbody>
</table>
## Allocation concealment (selection bias)

<table>
<thead>
<tr>
<th>Risk Level</th>
<th>Comment</th>
</tr>
</thead>
</table>
| Low        | Quote from publication: “Envelopes were kept in a locked room, accessed only by the trial nurse to minimise opportunities for tampering, and they were opened by the patient in the presence of three members of the research team to ensure that no changes were made to allocation.”  
Comment: allocation concealment adequate |

## Blinding of participants and personnel (performance bias)

<table>
<thead>
<tr>
<th>Risk Level</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>Quote from publication: participants and personnel not blinded</td>
</tr>
</tbody>
</table>

## Blinding of outcome assessment (detection bias)

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Risk Level</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recurrence Free Survival</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
</tbody>
</table>
| QOL                  | High risk  | Quote from publication: “This study was nonblinded because the different incisions would be difficult to camouflage.”  
Comment: participant-reported outcomes; participants not blinded |
| Complications        | High risk  | Quote from publication: “This study was nonblinded because the different incisions would be difficult to camouflage.”  
Comment: no outcome assessor blinding; study does not report the assessor |
| Transfusion Rates    | Unclear risk | not reported |
| Hospital Stay        | Low risk   | Comment: unlikely to be affected by non-blinding |
| Positive Margin Rates| Low risk   | Comment: unlikely to be affected by non-blinding |
| Complications/ Transfusion/ Hospital Stay/ Positive Margins | Low risk | Comment: All randomised participants were included in the analysis for these outcomes |
| QOL                  | High risk  | Quote from publication: “Overall, 53 patients completed the QoL questionnaire. One questionnaire was analysed per patient |
Khan 2016  (Continued)

Incomplete outcome data (attrition bias) Recurrence Free Survival
Unclear risk

Comment: In the RARC group, 20 participants were randomised, and 15 (75%) participants returned surveys. In the ORC group, 20 participants were randomised, and 16 (80%) participants returned surveys.

Incomplete questionnaires were excluded.

Nix 2010

Methods
• Study design: randomised noninferiority single-centre study
• Study period: April 2008 and January 2009
• Study setting: hospital based - University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
• LN yield was selected as the primary end point used for power analysis
• The null hypothesis was that mean LN yield for open cystectomy was higher than that for robotic cystectomy. A sample size of 20 participants per arm was calculated to provide 80% power and a 0.05 type 1 error rate to demonstrate the noninferiority of open to robotic cystectomy with respect to LN count based on a critical difference of 4 LNs. The 90% one-sided CI of this difference is reported because of the 5% significance used for the sample size calculation. If the upper level of this CI is > 4, the null hypothesis cannot be rejected and noninferiority has not been achieved.

Participants

Adults undergoing radical cystectomy (n = 41)
Diagnostic and inclusion criteria:
• Clinically localised urothelial carcinoma of the bladder
• Decision for surgical candidacy was based on the participant’s overall health status primarily with regard to ability to tolerate the pneumoperitoneum and steepness of the Trendelenburg position associated with the robotic approach.

Exclusion criteria:
• Unsuitable surgical candidates for either approach
• Those not allowing randomisation
• Those with preconceived preference for a specific surgical modality

Interventions
Cohort 1 = ORC with urinary diversion and PLND (n = 20)
Cohort 2 = RARC with extracorporeal urinary diversion and PLND (n = 21)
• Lymphadenectomy template: obturator, external iliac, hypogastric, and common iliac LN chains (did not include a paraaortic or paracaval dissection)
• Surgeon experience:
  ○ Experience of > 75 robotic cystectomy cases and of > 400 open cystectomy
### Nix 2010  (Continued)

<table>
<thead>
<tr>
<th>procedures</th>
<th>◦ Same primary surgeon and experienced surgical team in both groups</th>
</tr>
</thead>
</table>
| **Demographic data: RARC vs ORC** | Mean age years = 67.4 vs 69.2  
Male:Female = 14:7 vs 17:3  
Body mass index, kg/m², mean = 27.5 vs 28.4 |

### Outcomes
- EBL
- Operative time
- Complications
- Recovery of bowel function
- Narcotic usage
- Length of stay when assessed
- Margin status
- Lymph node count
- Time to adjuvant chemotherapy

### Funding sources
None

### Declarations of interest
None

### Notes
Language of publication: English

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias) | Low risk | **Quote from publication:** “The randomizations schema was performed with five sequential patients undergoing an approach before alternating surgical modality.”  
**Comment:** random sequence generation adequate |
| Allocation concealment (selection bias) | High risk | **Quote from publication:** “The randomization schema was performed with five sequential patients undergoing an approach before alternating surgical modality. This scheme was chosen, as opposed to randomizing each sequential patient, for the purpose of resident education. We believed that alternating each sequential surgery as to approach would make it significantly more difficult for residents to progress through their knowledge and acquisition of proficiency in each of the individual procedures.”  
**Comment:** allocation concealment inadequate |
<table>
<thead>
<tr>
<th>Bias</th>
<th>Risk</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td><strong>Comment:</strong> participants and personnel not blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td><strong>Comment:</strong> not reported</td>
</tr>
<tr>
<td><strong>Recurrence Free Survival</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td><strong>Comment:</strong> not applicable as not reported</td>
</tr>
<tr>
<td><strong>QOL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td><strong>Comment:</strong> no report on who collected outcomes and if they were blinded to the procedure</td>
</tr>
<tr>
<td><strong>Complications</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td><strong>Comment:</strong> not applicable as not reported</td>
</tr>
<tr>
<td><strong>Transfusion Rates</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td><strong>Comment:</strong> unlikely to be affected by non-blinding</td>
</tr>
<tr>
<td><strong>Hospital Stay</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td><strong>Comment:</strong> unlikely to be affected by non-blinding</td>
</tr>
<tr>
<td><strong>Positive Margin Rates</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td><strong>Comment:</strong> all randomised participants included in analysis for these outcomes</td>
</tr>
<tr>
<td><strong>Complications/Transfusion/Hospital Stay/Positive Margins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td><strong>Comment:</strong> not applicable as not reported</td>
</tr>
<tr>
<td><strong>QOL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td><strong>Comment:</strong> not reported</td>
</tr>
<tr>
<td><strong>Recurrence Free Survival</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>No protocol published</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>None</td>
</tr>
</tbody>
</table>
## Methods
- **Study design:** pilot prospective RCT
- **Study date:** July 2009 to June 2011
- **Study setting:** single-institution study—University of Texas Health Sciences Center at San Antonio, San Antonio, Texas, USA
- **Pilot trial to establish**
  - Feasibility and safety of the robotic approach
  - Preliminary data to determine statistical analyses and outcome measures for a phase 3 multi-institutional clinical trial

## Participants
**Adults undergoing radical cystectomy (n = 40)**

**Diagnostic criteria:**
- Biopsy-proven bladder cancer of clinical stage T1-T3, N0, M0

**Inclusion criteria:**
- Candidates for an open or robotic approach at the discretion of the treating surgeon

**Exclusion criteria:**
- Inability to give informed consent
- Multiple prior abdominal and pelvic open surgical procedures that would preclude a safe robotic approach
- Morbid obesity that would preclude the robotic approach
- Clinical T4 bladder cancer
- Clinical lymph node-positive bladder cancer with grossly enlarged pelvic or retroperitoneal lymph nodes
- Any preexisting condition that precludes safe initiation or maintenance of pneumoperitoneum for a prolonged period
- Age younger than 30 or older than 90 years
- Pregnancy

**Demographic data: RARC vs ORC**
- Median age years (IQR) = 69.5 (62.3 to 74) vs 64.5 (59.8 to 72.3)
- Male:Female = 18:2 vs 16:4
- Body mass index, kg/m², median (IQR) = 27.6 (24.2 to 29.9) vs 28.3 (26.1 to 32.3)

## Interventions
- **Cohort 1 = ORC with urinary diversion and PLND (n = 20)**
- **Cohort 2 = RARC with open urinary diversion and PLND (n = 20)**
  - The type of urinary diversion was performed at the discretion of the surgeon. The study does not explicitly state if the urinary diversion was performed with an extracorporeal or intracorporeal approach.
  - **Lymphadenectomy template:** Lymph node dissection for both groups was performed superiorly to the level of the ureteral crossing of the common iliac vessels, including the internal iliac artery and the obturator fossa, and laterally to the genitofemoral nerve, including the tissue overlying the psoas muscle.
  - **Surgeon experience:** The primary faculty involved in the study had an independent experience of more than 100 ORCs and had performed approximately 50 RARCs.
  - **Number of conversions from RARC to ORC:** 0
  - **Number of participant cross-overs to ORC after randomising to RARC:** 0

## Outcomes
- Establish the feasibility of randomising participants
- Obtain preliminary data on oncological efficacy, perioperative outcomes, and HRQoL outcomes
Parekh 2013  (Continued)

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td><em>Quote from publication:</em> “Patients who met the inclusion criteria were randomized to open or robotic radical cystectomy at their preoperative clinic visit using a computerized randomization program (<a href="http://www.randomization.com">www.randomization.com</a>) (see figure). This program generated a list of surgical slots numbered 1 through 60, and randomly assigned open or robotic assisted cystectomy to each slot (30 slots for each procedure).” <em>Comment:</em> random sequence generation adequate</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td><em>Quote from publication:</em> “Each assignment was placed in a sealed envelope with the corresponding slot number written on the outside. At the time of consent the lowest numbered envelope remaining was opened and the patient was assigned to the surgical procedure listed on the piece of paper inside the envelope.” <em>Comment:</em> allocation concealment adequate</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td><em>Comment:</em> participants and personnel not blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Recurrence Free Survival</td>
<td>Unclear risk</td>
<td><em>Comment:</em> not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) QOL</td>
<td>High risk</td>
<td><em>Quote from publication:</em> “The surgical team and the patient were then made aware of the type of surgery.” <em>Comment:</em> Participants were aware of the approach they had; hence there would have...</td>
</tr>
<tr>
<td>Bias</td>
<td>Risk Level</td>
<td>Comment</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Complications</td>
<td>Unclear risk</td>
<td>The study does not state who the outcome assessor was; it is unclear if the assessor was blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Transfusion Rates</td>
<td>Low risk</td>
<td>unlikely to be affected by non-blinding</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Hospital Stay</td>
<td>Low risk</td>
<td>unlikely to be affected by non-blinding</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Positive Margin Rates</td>
<td>Low risk</td>
<td>unlikely to be affected by non-blinding</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Complications/Transfusion/Hospital Stay/Positive Margins</td>
<td>Low risk</td>
<td>Most randomised participants were included in the analysis for these outcomes</td>
</tr>
</tbody>
</table>
| Incomplete outcome data (attrition bias) QOL | High risk | "The study is limited by the response rate to the questionnaires, with sampling at only 50% for some time periods, which only underscores the difficulty of obtaining prospective data with regard to HRQoL."
| Recurrence Free Survival | Unclear risk | not reported                                                          |
| Selective reporting (reporting bias) | Low risk | All predefined outcomes measured                                       |
| Other bias | Low risk | None                                                                    |
Methods
- Study design: multicentre, open-label, randomised, phase 3, noninferiority trial
- Study setting: 15 medical centres in the USA

Participants
**Adults undergoing radical cystectomy**

**Diagnostic criteria and inclusion criteria:**
- Biopsy-proven clinical stage T1-T4, N0-N1, M0 bladder cancer or refractory carcinoma in situ
- Age of 18 years or older

**Exclusion criteria:**
- Open abdominal or pelvic surgery or any preexisting health condition that would preclude safe initiation or maintenance of pneumoperitoneum
- Pregnant women

Interventions
- Intention-to-treat analysis
- Cohort 1 = ORC with urinary diversion and PLND (n = 159)
- Cohort 2 = RARC with open urinary diversion and PLND (n = 153)
- All urinary diversions were extracorporeal.
- **Lymphadenectomy template:** Extent of pelvic lymph node dissection (standard or extended) was based on institutional preference.
- **Surgeon experience:** Surgeons performing RARC and/or ORC must have performed ≥10 procedures each over the 1 year before approval as a study site.
- Use of chemotherapy was based on institutional preference.

Outcomes

**Primary outcome**
- 2-year progression-free survival

*Quote from publication:* "Disease progression was determined on the basis of radiographical or pathological evidence of disease, or death from disease according to Response Evaluation Criteria in Solid Tumours criteria version 1.1."

**Secondary outcomes**
- Blood loss
- Blood transfusion rates
- Surgical margin status
- Number of lymph nodes
- Operating time
- Length of hospital stay
- 90-day surgical complications
- 3- and 6-month health-related QoL outcomes

*Quote from publication:* "Change in baseline serum haemoglobin, creatinine, and albumin concentrations at 4-6 weeks, and at 3, 6, 12, 24, and 36 months, intraoperative fluid requirements, and analgesic requirements."

**Exploratory end points**
- Overall survival

*Quote from publication:* "Activities and instrumental activities of daily living scores, hand grip strength, and timed up and go walking test outcomes, assessed at 4-6 weeks, 3 months, and 6 months."

Funding sources
- National Institutes of Health National Cancer Institute
Declarations of interest

*Quote from publication:* “EPC reports personal fees from Intuitive Surgical outside the submitted work. MEW reports grants from the National Institutes of Health (NIH) during the study, and outside the submitted work. AZW reports grants from the University of Michigan during the study. BRK reports grants from the National Cancer Institute during the study; and grants from Photocure, Roche-Genentech, Genomic Health, Myriad Genetics, Spectrum, and FKD Therapies, outside the submitted work. MT reports grants from the NIH during the study. TLK reports grants from the NIH during the study. DAB reports grants from the NIH, during the study; and personal fees from AstraZeneca, Tolmar Pharmaceuticals, and Janssen, outside the submitted work. ASK reports advisory board fees from Profound, Sanofi-Aventis, and Janssen, outside the submitted work. CJW reports grants from Myriad Genetics and personal fees from Abbott Molecular, outside the submitted work. MSC has served on advisory boards for Astellas Pharma US, MDxHealth, Janssen, Bayer Healthcare, CicloMed, Abbott Laboratories, Tolmar Pharmaceuticals, Genomic Health, Altor Bioscience, Photocure, and Takeda Pharmaceutical; and reports consultancy fees from Myovant Sciences, TesoRx Pharma, and Pacific Edge Diagnostics. All other authors declare no competing interests.”

Notes

Language of publication: English

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td><em>Quote from study:</em> “By use of a dynamic balancing algorithm, patients were centrally randomly assigned (1:1) via a web-based system, to receive open cystectomy or robotic cystectomy. Using each institution as a block, the dynamic allocation procedure allocated an approximately equal number of patients to treatment groups to minimise imbalance between groups, stratified by type of urinary diversion (incontinent or continent), clinical T stage (carcinoma in situ, T1-T2, or T3-T4), and Eastern Cooperative Oncology Group (ECOG) performance status (0-1, or ≥2). On accrual a hierarchical decision-rule was applied, and the allocation was deterministic if certain predefined limits were exceeded, and random otherwise.”</td>
</tr>
</tbody>
</table>

| Allocation concealment (selection bias)  | Low risk           | *Quote from study:* “By use of a dynamic balancing algorithm, patients were centrally randomly assigned (1:1) via a web-based system, to receive open cystectomy or robotic cystectomy. Using each institution as a block, the dynamic allocation...” |
procedure allocated an approximately equal number of patients to treatment groups to minimise imbalance between groups, stratified by type of urinary diversion (incontinent or continent), clinical T stage (carcinoma in situ, T1-T2, or T3-T4), and Eastern Cooperative Oncology Group (ECOG) performance status (0-1, or =2). On accrual a hierarchical decision-rule was applied, and the allocation was deterministic if certain predefined limits were exceeded, and random otherwise.

<table>
<thead>
<tr>
<th>Blinding of participants and personnel (performance bias)</th>
<th>High risk</th>
<th>Comment: in view of the nature of the study, unlikely to be blinded</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>High risk</td>
<td>Quote from study: “Treatment allocation was only masked from pathologists, who analysed the cystectomy specimens.”</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>High risk</td>
<td>Quote from study: “Treatment allocation was only masked from pathologists, who analysed the cystectomy specimens.”</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>High risk</td>
<td>Quote from study: “Treatment allocation was only masked from pathologists, who analysed the cystectomy specimens.”</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>High risk</td>
<td>Quote from study: “Treatment allocation was only masked from pathologists, who analysed the cystectomy specimens.”</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td>Unlikely to be affected by nonblinding</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td>Unlikely to be affected by nonblinding</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td>Quote from study: “Treatment allocation was only masked from pathologists, who analysed the cystectomy specimens.”</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>Comment: Most randomised participants were included in analysis for these outcomes</td>
</tr>
</tbody>
</table>
Incomplete outcome data (attrition bias) QoL

Comment: At 6 months, QoL data were available for only 198 participants (63.4%)

Incomplete outcome data (attrition bias) Recurrence Free Survival

Quote from study: “Between July 1, 2011, and Nov 18, 2014, 350 patients were randomly assigned to treatment: 176 to the robotic cystectomy group and 174 to the open cystectomy group. Of the 176 patients who were randomly assigned to receive robotic cystectomy, 17 (10%) patients did not have surgery and nine (5%) patients had a different surgery to that they were assigned. Of the 174 patients assigned to receive open cystectomy, 21 (12%) patients did not have surgery and one (1%) patient had robotic cystectomy instead of open cystectomy.”

Selective reporting (reporting bias)

Comment: all predefined outcomes measured

Other bias

Comment: nil

CI: confidence interval; EBL: estimated blood loss; FACT-VCI: Functional Assessment of Cancer Therapy -Vanderbilt Cystectomy Index; HRQoL: health-related quality of life; IQR: interquartile range; ITT: intention-to-treat; LN: lymph node; LOS: length of (hospital) stay; LRC: laparoscopic radical cystectomy; MIBC: muscle-invasive bladder cancer; NMIBC: non-muscle-invasive bladder cancer; ORC: open radical cystectomy; PLND: pelvic lymph node dissection; QoL: quality of life; RARC: robotic-assisted radical cystectomy; RC: radical cystectomy; RCT: randomised controlled clinical trial; SD: standard deviation.

Characteristics of excluded studies  [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anderson 2013</td>
<td>Not a randomised controlled study. In this study, benign ureteroenteric anastomotic stricture rates of open and robot assisted laparoscopic radical cystectomy were compared using a prospectively maintained database</td>
</tr>
<tr>
<td>Atmaca 2015</td>
<td>Not a randomised controlled study. Retrospective comparison of open vs totally intracorporeal robotic-assisted radical cystectomy, bilateral extended pelvic lymph node dissection, and Studer urinary diversion. Researchers evaluated operative and postoperative parameters, pathological parameters, complications, and functional outcomes</td>
</tr>
<tr>
<td>Bak 2016</td>
<td>Although not clearly specified, this appears to be a nonrandomised retrospective observational study</td>
</tr>
<tr>
<td>Study</td>
<td>Methodology</td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
</tr>
<tr>
<td>Borza 2017</td>
<td>Not a randomised controlled study</td>
</tr>
<tr>
<td>Cusano 2016</td>
<td>Not a randomised controlled study</td>
</tr>
<tr>
<td>Galich 2006</td>
<td>Not a randomised controlled study</td>
</tr>
<tr>
<td>Gandaglia 2016</td>
<td>Not a randomised controlled study</td>
</tr>
<tr>
<td>Ginot 2016</td>
<td>Not a randomised controlled study</td>
</tr>
<tr>
<td>Gondo 2012</td>
<td>Not a randomised controlled study</td>
</tr>
<tr>
<td>Khan 2012</td>
<td>Not a randomised controlled study</td>
</tr>
<tr>
<td>Koupparis 2015</td>
<td>Not a randomised controlled study</td>
</tr>
<tr>
<td>Lee 2011</td>
<td>Not a randomised controlled study</td>
</tr>
<tr>
<td>Li 2016</td>
<td>Not a randomised controlled study</td>
</tr>
<tr>
<td>Martin 2011</td>
<td>Not a randomised controlled study</td>
</tr>
<tr>
<td>Matulewicz 2016</td>
<td>Not a randomised controlled study</td>
</tr>
<tr>
<td>Musch 2014</td>
<td>Not a randomised controlled study</td>
</tr>
<tr>
<td>Nepple 2013</td>
<td>Not a randomised controlled study</td>
</tr>
<tr>
<td>Ng 2010</td>
<td>Not a randomised controlled study</td>
</tr>
<tr>
<td>Nguyen 2015</td>
<td>Not a randomised controlled study</td>
</tr>
<tr>
<td>Study</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
</tr>
<tr>
<td>Rhee 2006</td>
<td>Not a randomised controlled study. This prospective comparative study compared estimated blood loss (EBL), transfusion requirements, operative duration, hospital stay, and body mass index (BMI) between ORC and RARC.</td>
</tr>
<tr>
<td>Satkunasivam 2016</td>
<td>Not a randomised controlled study. This retrospective study compared urodynamic features of intracorporeal orthotopic neobladder and bladder cancer-specific and general health-related quality of life between RARC and ORC.</td>
</tr>
<tr>
<td>Sharma 2017</td>
<td>Not a randomised controlled study. This retrospective study compared pathological and postoperative outcomes of RARC vs open radical cystectomy (ORC) with high-risk disease (pT3/T4).</td>
</tr>
<tr>
<td>Styn 2012</td>
<td>Not a randomised controlled study. This matched-pair analysis compared ORC and RARC. Researchers match-paired age, sex, urinary diversion, and clinical stage, and they compared perioperative complications and pathological outcomes.</td>
</tr>
<tr>
<td>Tan 2016</td>
<td>Not a randomised controlled study. Investigators compared early oncological outcomes and cancer recurrence sites among patients undergoing ORC and RARC with intracorporeal urinary diversion (iRARC).</td>
</tr>
<tr>
<td>Wang 2008</td>
<td>Not a randomised controlled study. This prospective study compared estimated blood loss (EBL), transfusion requirement, operative duration, time to resumption of regular diet, hospital stay, complication rates, and pathological outcomes between ORC and RARC.</td>
</tr>
<tr>
<td>Winters 2016</td>
<td>Not a randomised controlled study. This study compared perioperative surgical outcomes among elderly patients.</td>
</tr>
</tbody>
</table>

BMI: body mass index; EBL: estimated blood loss; ERAS: Enhanced recovery after surgery; HRQoL: health-related quality of life; iRARC: intracorporeal urinary diversion; LRC: laparoscopic radical cystectomy; ORC: open radical cystectomy; RARC: robotic-assisted radical cystectomy; RFS: Recurrence-free survival.

**Characteristics of ongoing studies**  
*ordered by study ID*

**Kelly, Catto 2017**

<table>
<thead>
<tr>
<th>Trial name or title</th>
<th>IROC (Trial to Compare Robotically Assisted Radical Cystectomy With Open Radical Cystectomy)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Phase III multicentre randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients with non-muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) who had selected radical cystectomy for treatment of bladder cancer; planned accrual of 320 participants</td>
</tr>
<tr>
<td>Interventions</td>
<td>Robotically assisted radical cystectomy and intracorporeal urinary diversion vs open radical cystectomy</td>
</tr>
</tbody>
</table>
| Outcomes            | Primary outcome measures:  
  - Days at home within 90 days of surgery  
Secondary outcome measures: |
### Kelly, Catto 2017 (Continued)

- by WHODAS version 2.0
- Quality of life measured by EQ-5D-5L Health Questionnaire and EORTC QLQ-C30 version 3

<table>
<thead>
<tr>
<th>Starting date</th>
<th>01/03/2017 (estimated study completion date: 15 February 2020)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact information</td>
<td>Chris Brew-Graves; 0207 679 9280; <a href="mailto:situ.iroc@ucl.ac.uk">situ.iroc@ucl.ac.uk</a></td>
</tr>
<tr>
<td>Notes</td>
<td>ClinicalTrials.gov identifier (NCT number): NCT03049410</td>
</tr>
</tbody>
</table>

### Analysis 1.1. Comparison 1: Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 1: Recurrence-free survival.

#### Review: Robotic versus open radical cystectomy for bladder cancer in adults

**Comparison:** 1 Robotic-assisted laparoscopic versus open radical cystectomy

**Outcome:** 1 Recurrence-free survival

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>RARC</th>
<th>ORC</th>
<th>log [Hazard Ratio] (SE)</th>
<th>Hazard Ratio (IV, Random, 95% CI)</th>
<th>Weight</th>
<th>Hazard Ratio (IV, Random, 95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bochner 2015</td>
<td>60</td>
<td>58</td>
<td>0.239 (0.284)</td>
<td>1.27 [0.73, 2.22]</td>
<td>31.5 %</td>
<td>1.27 [0.73, 2.22]</td>
</tr>
<tr>
<td>Parekh 2018</td>
<td>159</td>
<td>153</td>
<td>-0.0408 (0.1924)</td>
<td>1.05 [0.77, 1.43]</td>
<td>68.5 %</td>
<td>1.05 [0.77, 1.43]</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td>219</td>
<td>211</td>
<td></td>
<td><strong>100.0 %</strong></td>
<td><strong>1.05 [0.77, 1.43]</strong></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: \( \tau^2 = 0.0; \text{Chi}^2 = 0.67, df = 1 (P = 0.41); I^2 = 0.0\%

Test for overall effect: \( Z = 0.30 \text{ (P = 0.77)} \)

Test for subgroup differences: Not applicable
### Analysis 1.2. Comparison of Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 2

**Major postoperative complication rates (Clavien 3 to 5).**

**Review:** Robotic versus open radical cystectomy for bladder cancer in adults

**Comparison:** Robotic-assisted laparoscopic versus open radical cystectomy

**Outcome:** Major postoperative complication rates (Clavien 3 to 5)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>RARC</th>
<th>ORC</th>
<th>Risk Ratio M H Random, 95% CI</th>
<th>Weight</th>
<th>Risk Ratio M H Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bochner 2015</td>
<td>13/60</td>
<td>12/58</td>
<td>23.3 % 1.05 [0.52, 2.10]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Khan 2016</td>
<td>7/20</td>
<td>4/20</td>
<td>10.1 % 1.75 [0.61, 5.05]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nix 2010</td>
<td>1/21</td>
<td>1/20</td>
<td>1.6 % 0.95 [0.06, 14.22]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parekh 2013</td>
<td>1/20</td>
<td>1/20</td>
<td>1.6 % 1.00 [0.07, 14.90]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parekh 2018</td>
<td>33/150</td>
<td>34/152</td>
<td>63.5 % 0.98 [0.64, 1.50]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>271</strong></td>
<td><strong>270</strong></td>
<td><strong>100.0 % 1.06 [0.76, 1.48]</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total events: 55 (RARC), 52 (ORC)

Heterogeneity: $\tau^2 = 0.0; \chi^2 = 4.99, df = 4 (P = 0.09); I^2 = 0.0$

Test for overall effect: $Z = 0.33 (P = 0.75)$

Test for subgroup differences: Not applicable
Analysis 1.3. Comparison 1 Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 3 Minor postoperative complication rates (Clavien 1 and 2).

Review: Robotic versus open radical cystectomy for bladder cancer in adults

Comparison: 1 Robotic-assisted laparoscopic versus open radical cystectomy

Outcome: 3 Minor postoperative complication rates (Clavien 1 and 2)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>RARC</th>
<th>ORC</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Khan 2016</td>
<td>4/20</td>
<td>10/20</td>
<td>11.6 %</td>
<td>0.40 [ 0.15, 1.07 ]</td>
<td></td>
</tr>
<tr>
<td>Nix 2010</td>
<td>6/21</td>
<td>9/20</td>
<td>15.3 %</td>
<td>0.63 [ 0.28, 1.46 ]</td>
<td></td>
</tr>
<tr>
<td>Parekh 2013</td>
<td>4/20</td>
<td>4/20</td>
<td>7.6 %</td>
<td>1.00 [ 0.29, 3.45 ]</td>
<td></td>
</tr>
<tr>
<td>Parekh 2018</td>
<td>68/150</td>
<td>71/152</td>
<td>65.6 %</td>
<td>0.97 [ 0.76, 1.24 ]</td>
<td></td>
</tr>
</tbody>
</table>

Total (95% CI) 211 212 100.0 % 0.82 [ 0.58, 1.17 ]

Total events: 82 (RARC), 94 (ORC)

Heterogeneity: Tau² = 0.03; Chi² = 3.74, df = 3 (P = 0.29); I² = 20% 

Test for overall effect: Z = 1.08 (P = 0.28)

Test for subgroup differences: Not applicable
### Analysis 1.4. Comparison | Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 4

**Transfusion rate.**

**Review:** Robotic versus open radical cystectomy for bladder cancer in adults

**Comparison:** Robotic-assisted laparoscopic versus open radical cystectomy

**Outcome:** Transfusion rate

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>RARC</th>
<th>ORC</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
<th>Weight</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parekh 2013</td>
<td>8/20</td>
<td>10/20</td>
<td>19.9 % 0.80 [0.40, 1.60]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parekh 2018</td>
<td>35/143</td>
<td>65/143</td>
<td>80.1 % 0.54 [0.38, 0.76]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>163</strong></td>
<td><strong>163</strong></td>
<td><strong>100.0 % 0.58 [0.43, 0.80]</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total events: 43 (RARC), 75 (ORC)

Heterogeneity: $\tau^2 = 0.00; \chi^2 = 1.02, df = 1 (P = 0.31); I^2 = 2%$

Test for overall effect: $Z = 3.40 (P = 0.00067)$

Test for subgroup differences: Not applicable
**Analysis 1.5. Comparison 1 Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 5 Hospital stay.**

Review: Robotic versus open radical cystectomy for bladder cancer in adults

Comparison: 1 Robotic-assisted laparoscopic versus open radical cystectomy

Outcome: 5 Hospital stay

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>RARC</th>
<th>ORC</th>
<th>Mean Difference</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Bochner 2015</td>
<td>60</td>
<td>8 (3)</td>
<td>58</td>
<td>8 (5)</td>
</tr>
<tr>
<td>Khan 2016</td>
<td>20</td>
<td>11.9 (6.2)</td>
<td>20</td>
<td>14.4 (5.9)</td>
</tr>
<tr>
<td>Nix 2010</td>
<td>21</td>
<td>5.1 (2.41)</td>
<td>20</td>
<td>6 (2.41)</td>
</tr>
<tr>
<td>Parekh 2013</td>
<td>20</td>
<td>6.625 (1.125)</td>
<td>20</td>
<td>6.83 (0.825)</td>
</tr>
<tr>
<td>Parekh 2018</td>
<td>150</td>
<td>6 (0.833)</td>
<td>152</td>
<td>7 (0.66)</td>
</tr>
</tbody>
</table>

**Total (95% CI)**

```
<table>
<thead>
<tr>
<th>N</th>
<th>Mean(SD)</th>
<th>N</th>
<th>Mean(SD)</th>
<th>Mean Difference</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>271</td>
<td>270</td>
<td>100.0 %</td>
<td>-0.67 [ -1.22, -0.12 ]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
```

Heterogeneity: \( \tau^2 = 0.17; \chi^2 = 8.29, \text{df} = 4 (P = 0.08); I^2 = 52\%

Test for overall effect: \( Z = 2.38 (P = 0.017) \)

Test for subgroup differences: Not applicable
**Analysis 1.6. Comparison of Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 6 Quality of life.**

**Review:** Robotic versus open radical cystectomy for bladder cancer in adults

**Comparison:** Robotic-assisted laparoscopic versus open radical cystectomy

**Outcome:** Quality of life

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>RARC</th>
<th>ORC</th>
<th>Std. Mean Difference</th>
<th>Weight</th>
<th>Std. Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
<td>IV,Random,95% CI</td>
</tr>
<tr>
<td>Bochner 2015</td>
<td>23</td>
<td>76 (11)</td>
<td>30</td>
<td>78 (23)</td>
<td>19.4%</td>
</tr>
<tr>
<td>Khan 2016</td>
<td>15</td>
<td>122.3 (17.1)</td>
<td>16</td>
<td>124.9 (12.7)</td>
<td>11.5%</td>
</tr>
<tr>
<td>Parekh 2018</td>
<td>95</td>
<td>126 (27.8)</td>
<td>91</td>
<td>127.5 (28.2)</td>
<td>69.2%</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>133</strong></td>
<td><strong>137</strong></td>
<td><strong>100.0%</strong></td>
<td><strong>-0.08 [-0.32, 0.16]</strong></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $\tau^2 = 0.0$, $\chi^2 = 0.10$, df = 2 ($P = 0.95$); $I^2 = 0.0\%$

Test for overall effect: $Z = 0.63$ ($P = 0.53$)

Test for subgroup differences: Not applicable
Analysis 1.7. Comparison 1 Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 7 Positive margin.

Review: Robotic versus open radical cystectomy for bladder cancer in adults

Comparison: 1 Robotic-assisted laparoscopic versus open radical cystectomy

Outcome: 7 Positive margin

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>RARC</th>
<th>ORC</th>
<th>Risk Ratio M-H,Random,95% CI</th>
<th>Weight</th>
<th>Risk Ratio M-H,Random,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bochner 2015</td>
<td>2/60</td>
<td>3/58</td>
<td>17.1 % 0.64 [0.11, 3.72]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Khan 2016</td>
<td>3/20</td>
<td>2/20</td>
<td>18.7 % 1.50 [0.28, 8.04]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nix 2010</td>
<td>0/21</td>
<td>0/20</td>
<td>Not estimable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parekh 2013</td>
<td>1/20</td>
<td>1/20</td>
<td>7.2 % 1.00 [0.07, 14.90]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parekh 2018</td>
<td>9/150</td>
<td>7/152</td>
<td>56.9 % 1.30 [0.50, 3.41]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>271</strong></td>
<td><strong>270</strong></td>
<td><strong>100.0 % 1.16 [0.56, 2.40]</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total events: 15 (RARC), 13 (ORC)
Heterogeneity: Tau^2 = 0.0; Chi^2 = 0.59, df = 3 (P = 0.90); I^2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable

APPENDICES

Appendix 1. Electronic search strategies

<table>
<thead>
<tr>
<th>Database</th>
<th>Search terms</th>
</tr>
</thead>
</table>
| CENTRAL    | #1 MeSH descriptor: [Robotics] explode all trees  
#2 (robot*):kw,ti,ab near/3 (surgery* or assist):kw,ti,ab  
#3 #1 or #2  
#4 MeSH descriptor: [Cystectomy] explode all trees  
#5 (surg* or excis*):kw,ti,ab near/3 (urin* or bladder*):kw,ti,ab  
#6 #4 or #5  
#7 #3 and #6  
#8 (robot*):kw,ti,ab near/3 (cystectom*):kw,ti,ab  
#9 #7 or #8  |

Robotic versus open radical cystectomy for bladder cancer in adults (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
<table>
<thead>
<tr>
<th>Database</th>
<th>Search Terms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web of Science</td>
<td>1. (TOPIC:(cystostomy) AND TOPIC: (robotic)) 2. (TOPIC:(cystostomy) AND TOPIC: (robotic)AND TOPIC: (randomizedcontrolled trial)) 3. TITLE: (cystectomy) AND TITLE: (robotic) AND TITLE: (randomized controlled trial) 4. TITLE: (cystectomy) AND TITLE: (randomized controlled trial)</td>
</tr>
<tr>
<td>Cancer Research UK</td>
<td>1. Bladder cancer trials 2. Robotic cystectomy</td>
</tr>
<tr>
<td>Institute of Cancer Research</td>
<td>1. Bladder cancer trials 2. Robotic cystectomy</td>
</tr>
<tr>
<td>ClinicalTrials.gov</td>
<td>1. robotic</td>
</tr>
<tr>
<td>BioMed Central ISRCTN</td>
<td>1. robotic Remove filter within Condition: bladder cancer Remove filter Interventions: cystectomy Remove filter</td>
</tr>
<tr>
<td>WHO ICTRP</td>
<td>1. bladder cancer AND cystectomy AND Robot 2. bladder cancer AND cystectomy AND Robot AND trial</td>
</tr>
<tr>
<td>Terms used</td>
<td>robotic cystectomy  robot cystectomy robot assisted cystectomy robotic radical cystectomy</td>
</tr>
</tbody>
</table>
CONTRIBUTIONS OF AUTHORS

BR: wrote the review and contributed to data extraction and analysis, concept, and data interpretation.
JB: contributed to data extraction and analysis and drafting work.
NV: contributed to text of review and to data analysis, concept, and data interpretation.
JA: contributed to text of review and to data analysis, concept, and data interpretation.
TL: contributed to text of review and to data analysis, concept, and data interpretation.
KA: contributed to text of review and to concept.
MSK: contributed to text of review, concept, and data interpretation.
PD: contributed to text of review, concept, and data interpretation.
KG: contributed to text of review and to concept and data interpretation.
PLC: contributed to text of review and to interpretation of data and concept.
OMA: wrote the review and contributed to data extraction and analysis, concept, and data interpretation.

DECLARATIONS OF INTEREST

BR: none known.
JB: none known.
NV: none known.
JA: none known.
TL: none known.
KA: none known.
MSK: none known.
PD: none known.
KG: none known.
PLC: none known.
OMA: none known.

SOURCES OF SUPPORT
Internal sources
• None, Other.

External sources
• None, Other.

DIFFERENCES BETWEEN PROTOCOL AND REVIEW
• None

NOTES
We have based parts of the Methods section of the protocol for this review on a standard template developed by the Cochrane Metabolic and Endocrine Disorders Group that has been modified and adapted for use by the Cochrane Urology Group.